2022 World Conference on Lung Cancer (ePosters)-EP14.05-005. Survival of Small Cell Lung Cancer in Relation to Chemotherapy Dose Intensity

Pdf Summary

In a retrospective observational study, researchers analyzed the clinical data of 74 patients with small cell lung cancer (SCLC) who received treatment with standard platinum and etoposide chemotherapy between 2018 and 2022. The study aimed to determine the impact of chemotherapy dose intensity (DI) on overall survival (OS) and other relevant factors.<br /><br />The results showed that patients with SCLC in extensive disease (ED) who received a DI of less than 75% had a significantly worse OS. Patients with a better functional status (ECOG 1) and those who received consolidation thoracic radiotherapy had more favorable outcomes. The study suggests that optimizing support treatment to maintain DI would be recommended.<br /><br />The data analysis included 74 patients, with a median age of 68 years, all of whom were smokers. Most patients had comorbidities, and the majority had ED at diagnosis.<br /><br />The median OS for all patients was 7 months. In patients with ED, the median OS was 0 months for a DI of 0-49%, 6 months for a DI of 50-74%, and 11 months for a DI of 75-100%.<br /><br />In terms of functional status, patients with an ECOG score of 1 had a median OS of 9 months, while those with an ECOG score of 2 had a median OS of 6 months.<br /><br />Patients who received consolidation thoracic radiotherapy had a median OS of 15 months, while those who did not receive the treatment had a median OS of 6 months.<br /><br />The study emphasizes the aggressive nature of SCLC and its poor prognosis. The findings suggest that maintaining proper DI of chemotherapy and considering factors like functional status and thoracic radiotherapy can positively impact survival outcomes in patients with SCLC.

Asset Subtitle

Elisa María Fernández Pérez

Meta Tag

Speaker Elisa María Fernández Pérez

Topic Small Cell Lung Cancer and Neuro-endocrine Tumours - RW/SOC

Keywords

retrospective observational study

SCLC

chemotherapy

overall survival

functional status

thoracic radiotherapy

DI

data analysis

prognosis

survival outcomes